A recent study indicates that a chronic periodontal pathogen infection could result in the development of Alzheimer’s disease.
Browsing: Alzheimer’s disease
Some EU healthcare systems have been reported to lack the capacity to rapidly move an Alzheimer’s treatment from approval into widespread clinical use.
Researchers have determined that the blood–brain barrier could be used as a possible biomarker for Alzheimer’s disease; this could potentially result in earlier diagnosis of the disease.
In this week’s round-up, we cover the latest industry news from the US FDA and the halt of an Alzheimer’s drug following a toxic reaction.
Scientists have discovered a vicious feedback loop underlying brain degeneration in Alzheimer’s, which may explain why many drug trials have failed.
At AAIC 2018, we had the pleasure of speaking with Catherine Kaczorowski about the innovative work she is doing to accelerate drug discovery in Alzheimer’s disease.
We’re hosting a Twitter chat on World Alzheimer’s Day into all things dementia, such as public perception. Meet our panelists and join us at #TalkDementia.
In this interview, we spoke with Giovanni Frisoni about his talk on gut microbiome alterations and what impact this research could have for patients.
A drug that has been used to treat liver disease for decades may help to restore cells damaged by Alzheimer’s disease, a new study has revealed.
In a direct comparison, ProMIS Neurosciences’ oligomer-selective antibody (PMN310) reveals a potential advantage over other antibody therapeutics.